from your post I gather controls will be eligible for treatment with plasma-derived ATIII where available..almost seems like a non-inferiority would be most appropriate if an inordinately high proportion of docs, based on kybersept, already tend to treat with ATIII/no heparin, no?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.